HAART 200 Aortic Valve Annuloplasty Trial

N/ACompletedNCT02071849

Biostable Science & Engineering20 enrolled

Overview

The HAART 200 "Aortic Annuloplasty during Bicuspid Aortic Valve Reconstruction" Trial is a prospective, non-randomized, multi-center trial to evaluate the safety and effectiveness of the HAART 200 bicuspid annuloplasty ring when used to surgically stabilize the aortic valve annulus in patients undergoing repair of bicuspid aortic valves (BAV) for predominant aortic insufficiency (AI).

Aortic valve disease is the most common valvular heart disease with approximately 200,000 patients per year undergoing conventional aortic valve replacement in North America and Europe. Around 60% of valves have Aortic Stenosis (AS) and 40% of have Aortic Insufficiency, which is the failure of the aortic valve to close completely during diastole, causing blood to flow from the aorta back into the left ventricle. Bicuspid valve morphology is present in a fourth to a third of patients coming to surgical intervention, and constitutes a very important subset. Several conditions are associated with bicuspid disease, including ascending aortic or root aneurysms in up to a third. Traditional management of aortic valve and root disease has been with aortic valve replacement, with or without root replacement (Bentall Procedure). However, as has been observed in patients with mitral valve repair, the option of maintaining one's reconstructed native valve versus a replacement, either bioprosthetic or mechanical, can have multiple benefits. The advantages of repair include: the avoidance of prosthetic valve related complications and structural degeneration with bioprosthetic valves over 10-15 years and elimination of the need for anticoagulation and related problems with mechanical valves in younger patients. The significantly lower rate of endocarditis after repair is a major impetus to increasing performance of BAV reconstruction. Thus, aortic valve repair currently is established as an excellent option for patients with BAV. However, with connective tissue disorders being an inherent feature of BAV, outcomes have been less stable long-term than for trileaflet repair, primarily because of late annular redilatation in BAV disease. Therefore, this study is designed to evaluate the safety and effectiveness of annular stabilization with a bicuspid annuloplasty ring in patients undergoing repair of a bicuspid aortic valve for predominant aortic insufficiency.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Aortic Insufficiency

Interventions

HAART 200 Aortic Valve Annuloplasty DeviceDEVICE

Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. The subject is 18 years of age or older 2. The subject has bi-leaflet aortic valve morphology 3. The subject has documented aortic valve disease which may or may not include: * Aortic valve insufficiency * Ascending aortic or aortic root pathology * Other pathology of the ascending aorta that requires elective aortic replacement * Associated stable one or two vessel coronary disease requiring concomitant coronary bypass * Patients with recurrent severe AI (Grade 3 or 4) after prior bicuspid repair who are undergoing re-repair because of annular re-dilatation * All bicuspid annular and leaflet configurations will be included 4. The subject needs: * correction of BAV annular dilatation in patients with chronic AI and dilated annulus * restoration of a circular annular shape in patients with bicuspid valve and expansion of sinus to sinus dimensions * stabilization of annular geometry long-term in rare bicuspid valve patients with severe AI and minimal annular dilatation 5. The is willing to comply with specified follow-up evaluations, including transesophageal echocardiography (TEE) if there are inadequate images by transthoracic echocardiography (TTE) to assess the aortic valve 6. The subject has reviewed and signed the written informed consent form 7. The subject agrees to return for all follow-up evaluations for the duration of the study (i.e. geographically stable) Exclusion Criteria: 1. All patients will be excluded who require emergency surgery for any reason. 2. All the patients who have had a prior heart valve replacement 3. The subject's aortic valve morphology is not bicuspid. 4. The subject has active endocarditis 5. The subject has mixed stenosis and regurgitation of the aortic valve with predominant stenosis 6. Heavily calcified BAV valves, calcified aortic roots, or "porcelain aortas" 7. Leukopenia with a White Blood Cell (WBC) of less than 3000 8. Acute anemia with a Hgb less than 9mg% 9. Platelet count less than 100,000 cells/mm3 10. History of a defined bleeding diathesis or coagulopathy or the subject refuses blood transfusions 11. Active infection requiring antibiotic therapy (if temporary illness, subjects may enroll 2-4 weeks after discontinuation of antibiotics) 12. Subjects in whom transesophageal echocardiography (TEE) is contraindicated 13. Low Ejection Fraction (EF) \< 35% 14. Life expectancy \< 1 year, or severe comorbidities, such as dialysis or severe Chronic Obstructive Pulmonary Disease (COPD) 15. The subject is or will be participating in a concomitant research study of an investigational product or has participated in such a study within the 30 days prior to screening 16. The subject is a minor, an illicit drug user, alcohol abuser, prisoner, institutionalized, or is unable to give informed consent 17. The subject is pregnant or lactating 18. Recent (within 6 months) cerebrovascular accident (CVA) or a transient ischemic attack (TIA) 19. Myocardial Infarction (MI) within one month of trial inclusion 20. The subject has a known intolerance to titanium or polyester 21. The subject has documented unstable or \> 2 vessel coronary disease 22. The subject requires additional valve replacement or valve repair

Locations (4)

München Heart Center

München, Bavaria, Germany

Uniklinik Köln

Cologne, North Rhine-Westphalia, Germany

Klinik und Poliklinik für Herz- und Gefäßchirurgie

Hamburg, Germany

Klinikum Nürnberg Süd

Nuremberg, Germany

Outcomes

Primary Outcomes

Primary Safety Outcome Measure: Survival Defined as Survival Free From All Cause Death at 6 Months Postprocedure.

Time frame: 6 months postprocedure

Primary Efficacy Outcome Measure: Aortic Insufficiency (AI) at 6 Months

Aortic insufficiency assessed by transthoracic echocardiography and graded as None/Trace (0), Mild (1+), Moderate (2+), Moderately Severe (3+), or Severe (4+)

Time frame: 6 months postprocedure

Secondary Outcomes

Implant Procedure Success

Success is defined as the absence of specified adverse events evaluated through discharge following the procedure: - Aortic annular dissection, rupture, or leaflet damage - Mitral valve impingement due to implant - implant dehiscence/migration into aorta - implant dehiscence/migration into left ventricle - Hemodynamics requiring intervention - Other adverse event resulting in reoperation, explantation, or permanent disability.

Time frame: discharge or 14 days postprocedure, whichever comes first

Actuarial Freedom From Clinical Cardiovascular Events

Freedom from specified clinical cardiovascular events 6 months postprocedure: - Device-related mortality - Complete heart block - Structural device failure - Endocarditis - Periprosthetic leak or dehiscence - Thromboembolism - Bleeding Event - Native Valve Deterioration - Valve Thrombosis - Hemolysis - Reoperation and explant at 6 months

Time frame: 6 months postprocedure

Actuarial Freedom From Clinical Cardiovascular Events

Time frame: 2 years postprocedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.